Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

13 mai 2015 08h30 HE | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2015

PHILADELPHIA, May 13, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the three months ended March 31, 2015. The net loss (including non-cash effects)...
28 avr. 2015 08h30 HE | Source: AIM ImmunoTech Inc.

Midtown Partners & Co, LLC Initiates Coverage and Arrowhead b.i.d. Issues Coverage Update on Hemispherx Biopharma

PHILADELPHIA, April 28, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") reported today that Midtown Partners &Co, LLC initiates coverage of...
23 févr. 2015 08h30 HE | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma: Institute of Medicine, the Health Arm of the US National Academy of Sciences Reframes Chronic Fatigue Syndrome (CFS) as a "Systemic Exertion Intolerance Disease" (SEID)

PHILADELPHIA, Feb. 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced today that a new report, issued February 10, 2015 by the Institute of...
26 janv. 2015 08h30 HE | Source: AIM ImmunoTech Inc.

USAMRIID Reports Genetic Changes in Ebola Virus May Impede Potential Treatments

PHILADELPHIA, Jan. 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today that in a new publication in the journal mBio, scientists at...
12 janv. 2015 08h30 HE | Source: AIM ImmunoTech Inc.

Low Natural Killer (NK) Activity Observed Across the Chronic Fatigue Syndrome (CFS) Disease Spectrum

PHILADELPHIA, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has conducted new in vitro studies of natural killer...
09 janv. 2015 08h30 HE | Source: AIM ImmunoTech Inc.

Arrowhead Issues Diligence and Valuation Report on Hemispherx Biopharma

PHILADELPHIA, Jan. 9, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announces that Arrowhead BID issued an analyst report on Thursday, January...
16 déc. 2014 08h30 HE | Source: AIM ImmunoTech Inc.

Hemispherx's Ampligen(R) Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors

PHILADELPHIA, Dec. 16, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today further progress on developing Ampligen® (rintatolimod)...
17 nov. 2014 09h08 HE | Source: AIM ImmunoTech Inc.

Ampligen(R) Blocks Critical Ebola Viral Disease (EVD) Protein Which is Linked to High Mortality in Man

PHILADELPHIA, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today that it had received a new research report from Professor...
22 juil. 2014 08h30 HE | Source: AIM ImmunoTech Inc.

Hemispherx Achieves High Ranking in Sensitivity Testing Against MERS/SARS Coronaviruses Compared to Other Drugs

PHILADELPHIA, July 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that a new publication abstract in Infectious Disorder Drug Targets (2014 Jul 13. [Epub ahead of print])...

Page précédente